Program

Tuesday 14 MayWednesday 15 MayThursday 16 May
 

Tuesday 14 May

 Opening of the Workshop
 4:00 PM

Opening Remarks
David Burger, PharmD, PhD - Radboud University Medical Centre, the Netherlands

 
  Session 1 - 20 Years in Review
Chairs: David Burger & David Back
 
 4:15 PM

Drug-drug interactions: all you need to know beyond www.hiv-druginteractions.org
Marta Boffito, MD, PhD - Chelsea and Westminster Hospital, United Kingdom

 
 4:45 PM

Courtney Fletcher, PharmD

Stop measuring ARV levels in plasma!
Courtney Fletcher, PharmD - University of Nebraska, United States

 
 5:15 PM

Terrence Blaschke, MD

50% adherence is enough with modern ARVs, right?
Terrence Blaschke, MD - Stanford University, United States

 
 5:45 PM

Jonathan Schapiro, MD

Modern ARVs do not develop resistance, do they?
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 
 6:15PMRound-Table Discussion 
   
 Welcome Reception + Group Photo 
   
 

Wednesday 15 May

 Session 2 - Novel strategies for prevention and therapy
Chairs: Andrea Calcagno & Kimberly Scarsi
 8:30 AM

The ‘third wave’ of TB drug development: what’s on the horizon (for patients with or without HIV)
Kelly Dooley, MD, PhD - Johns Hopkins University, United States

 
 Abstract-driven Presentations
 9:00 AM

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine
Anthony Podany, PharmD - University of Nebraska Medical Center, United States

 #1
 9:15 AMIn silico design of a microarray patch as a multipurpose prevention technology
Rajith Rajoli - Univerisity Of Liverpool, United Kingdom

 #2
 9:30 AMPopulation pharmacokinetics of VRC01 in infants and adults
Jerry Li - University of California San Diego, United States
 #3
9:45 AMThe initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects
Samit Joshi, MD - ViiV Healthcare, United States
 #4
 10:00 AMDiscussion
 
   
10:15 AMMorning Coffee Break & Poster Session I (No. 19 - 36)
   
 Session 3 - Viral Hepatitis & Liver Disease
Chairs: Jennifer Kiser & Alice Tseng 
11:00 AM

Novel antiviral and immune targets to cure HBV
Fabien Zoulim, MD - INSERM, France

 
 11:30 AM

Pharmacological treatment of NASH
Sven Francque, MD, PhD - University Hospital Antwerp & University of Antwerp, Belgium

 
 Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare
Chair: Jonathan Schapiro
 
 

 

Opening Remarks
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 
 12:00 PM

Improved long acting drug delivery: What are the technologies?
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 
 12:20 PM

Long acting HIV drugs for treatment: Data and potential implementation
Charles Flexner, MD - Johns Hopkins University, United States

 
 12:40 PM

Long Acting HIV Drugs for Prevention: Data and Potential implementation
Laura Waters, MD - Central & North West London NHS Trust, Mortimer Market Centre, United Kingdom

 
  Closing Remarks 
 1:00 PMLunch Break
   
 Session 4 - Drug-drug interactions: evolving challenges
Chairs: Saye Khoo & Angela Kashuba
 2:00 PM

Clinical Case Presentation
Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool

 
 2:30 PM

ClinicalCasesDDI Website Launch
José Moltó, MD, PhD - Hospital Universitari Germans Trias i Pujol, Spain

 
 Abstract-driven Presentations
 2:40 PMChanges in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website
Sara Gibbons - University of Liverpool, United Kingdom
 #5
 2:55 PMDrugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction
Tess Martin - APHM La Timone, France
 #6
 3:10 PMEffect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy
Michelle Pham - University Of Nebraska Medical Center
 #7
 Discussion 
   
 3:30 PMAfternoon Coffee Break & Poster Session II (No. 37 - 48)
   
 4:15 PMDebate: Dual maintenance for HIV: Why fix it if it's not broken?
Moderator: Jonathan Schapiro
 
 

Pro Perspective
José Ramón Arribas, MD - Hospital La Paz, IdiPaz, Spain

 
 

Con Perspective
Andrew Hill, MD - University of Liverpool, United Kingdom

 
 Special Lecture
 5:00 PMRegulatory perspective on evaluating ARVs in during pregnancy
Kimberly Struble, PharmD - US Food & Drug Administration, United States
 
   
 7:00 PM Networking Dinner 
   
 

Thursday 16 May

 Session 5 - Special populations and adherence
Chairs: Terrence Blaschke & Tim Cressey
 8:30 AMSpecial Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)
Paul Domanico, PhD - Clinton Health Access Initiative, United States
 #8
 8:45 AMInfant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1
Laura Dickinson - University Of Liverpool, United Kingdom
 #9
 9:00 AMPharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum
Jeremiah Momper - University Of California San Diego, United States
 #10
 9:15 AMLow isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment
Marije Van Schalkwyk, MD - Stellenbosch University, South Africa
 #11
 9:30 AMPharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum
Kristina Brooks, PharmD - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States
 #12
 9:45 AMTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy
Jenna Yager - University of Colorado, United States
 #13
 10:00 AMAn exploration of adherence measures to detect recent changes in Truvada® dosing patterns
Daijha Anderson - University Of North Carolina Eshelman School Of Pharmacy, United States
 #14
   
 10:15 AMCoffee Break 
   
 11:00 AMShort Poster Presentations; "Best of Posters"
Moderator: Giovanni Di Perri & Marco Siccardi
 Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV
Felix Stader, University Hospital Basel, Switzerland
 #15
 Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy
Mary Gockenbach - US Food and Drug Administration, Division of Pediatrics and Maternal Health
 #16
 A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents
Bernard Ngara - University Of Zimbabwe College Of Health Sciences, Zimbabwe
 #17
 Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
Aarti Patel - Glaxosmithkline R&D, United Kingdom
 #18
 The Next 20 Years
Chairs: Charles Flexner & David Burger
 11:30 AM

CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD - University of Southern California Keck School of Medicine, United States

 
 12:00 PM

Owen, Andrew - 2019

Understanding the key determinants of performance for long-acting formulations
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 
 Closing Remarks
  

Jennifer Kiser, PharmD
University of Colorado Health Science Center, United States

 
 12:45 PMLunch